The estimated Net Worth of Robert Andrade is at least $2.25 Million dollars as of 1 April 2024. Mr. Andrade owns over 12,500 units of Fennec Pharmaceuticals Inc stock worth over $548,465 and over the last 7 years he sold FENC stock worth over $833,153. In addition, he makes $863,766 as Chief Financial Officer at Fennec Pharmaceuticals Inc.
Robert has made over 8 trades of the Fennec Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 12,500 units of FENC stock worth $65,750 on 1 April 2024.
The largest trade he's ever made was exercising 323,961 units of Fennec Pharmaceuticals Inc stock on 13 August 2020 worth over $599,328. On average, Robert trades about 21,831 units every 98 days since 2018. As of 1 April 2024 he still owns at least 104,271 units of Fennec Pharmaceuticals Inc stock.
You can see the complete history of Mr. Andrade stock trades at the bottom of the page.
Robert C. Andrade serves as Chief Financial Officer of the Company. Mr. Andrade has served as Chief Financial Officer since November 2015. Mr. Andrade was previously Chief Financial Officer and Director of Fennec from September 2009 until August 2013. In addition to his role with Fennec, Mr. Andrade was a private investor in 2015, and a senior analyst at Magnetar Capital from 2013 - 2014. Mr. Andrade graduated from University of Southern California, where he earned a Masters of Arts degree and Bachelor of Arts degree in economics.
As the Chief Financial Officer of Fennec Pharmaceuticals Inc, the total compensation of Robert Andrade at Fennec Pharmaceuticals Inc is $863,766. There are 2 executives at Fennec Pharmaceuticals Inc getting paid more, with Rostislav Raykov having the highest compensation of $1,477,140.
Robert Andrade is 39, he's been the Chief Financial Officer of Fennec Pharmaceuticals Inc since 2015. There are 9 older and no younger executives at Fennec Pharmaceuticals Inc. The oldest executive at Fennec Pharmaceuticals Inc is Anne McKay, 67, who is the Regulatory Consultant.
Over the last 10 years, insiders at Fennec Pharmaceuticals Inc have traded over $13,607,192 worth of Fennec Pharmaceuticals Inc stock and bought 1,966,488 units worth $9,890,813 . The most active insiders traders include Management Pr, Llcmancheste..., Spacavazza Paolo Cavazza En..., and Rosty Raykov. On average, Fennec Pharmaceuticals Inc executives and independent directors trade stock every 69 days with the average trade being worth of $442,734. The most recent stock trade was executed by Rosty Raykov on 31 August 2024, trading 2,431 units of FENC stock currently worth $13,419.
fennec pharmaceuticals inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the united states. its lead product pedmark, a formulation of sodium thiosulfate, which has completed the phase iii clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. the company was formerly known as adherex technologies inc. and changed its name to fennec pharmaceuticals inc. in september 2014. fennec pharmaceuticals inc. was founded in 1996 and is based in research triangle park, north carolina.
Fennec Pharmaceuticals Inc executives and other stock owners filed with the SEC include: